News from the Bench
Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.
Research More. Spend Less.
Spend $650 or more and get 20% off*
(*Offer valid in the US only. Expires June 30, 2017)
To Purchase # 9843S
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
Western blot analysis of extracts from HEK293 cells, untreated or treated with indicated concentrations of Geldanamycin for 20 hours, using IKKα Antibody #2682 showing IKKα degradation (upper). β-Actin Antibody #4967 was used as a loading control (lower).Learn more about how we get our images
Gallery: Geldanamycin #9843
Geldanamycin is supplied as 600 μg powder. Store at or below -20ºC. Before usage, dissolve the chemical in 1.08 ml DMSO to make 1 mM Geldanamycin. For working concentrations of 300 nM-1 μM, dilute 1:3000 to 1:1000. Treat cells with the desired concentration for 20-48 hours. Store liquid form at or below -20ºC.
.Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 1 week to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Geldanamycin (GA) is a naturally existing HSP90 inhibitor that belongs to the benzoquinone ansamycin family. GA binds to the amino terminal ATP-binding pocket of HSP90 and inhibits ATP binding and hydrolysis. HSP90 is a chaperone interacting with a wide variety of important target proteins for cell signaling and regulation during tumorgenesis (1,2). The binding of GA to HSP90 interferes with HSP-mediated target protein folding, leading to target aggregation and degradation (1-3). GA and its synthetic derivatives show higher affinity to HSP90 in tumor cells as compared to normal tissues and constitute a class of protential antitumor drugs (2-3).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.